While Pfizer is still the preferred vaccine for under 40s, those who don’t want to wait can now talk to their GP about getting an AstraZeneca shot. But what risks and benefits do you need to weigh up?
Articles on AstraZeneca vaccine
Displaying 21 - 40 of 156 articles
With higher rates of vaccination, the current COVID outbreaks may have been more easily managed.
Just like your memory, which improves by repeated viewing or listening with a break in between, our immune memory improves with repeated exposure.
Two doses have always been more protective than one, but the delta variant has made the benefit of a second vaccine much greater.
While it’s potentially promising, there’s not enough information yet to determine if the vaccine is safe and effective.
Our attitudes and behaviours are shaped by what others in society do. So there’s a real danger that vaccine hesitancy, when reported widely in the media, could catch on to more people.
Various companies use different ingredients and different delivery systems in their COVID-19 vaccines. Researchers are investigating whether it’s better for individuals to mix what’s available.
Experts are continually monitoring how well COVID vaccines are working, their side effects, and the amount of disease in the community. These factors can change, and advice will adapt accordingly.
Even if we came up with a definition of what makes the “best” vaccine, we don’t have the luxury of choice, when vaccines are in short supply.
If you have risk factors around blood clots, heart attack or stroke, this should actually be an impetus to get vaccinated sooner rather than later.
Both the AstraZeneca and Pfizer vaccines still work relatively well against it — though only after the second dose.
Hundreds of thousands of Canadians got a shot of AstraZeneca’s COVID-19 vaccine for their first dose. They now have a choice for their second dose: AstraZeneca again, or Pfizer or Moderna mRNA vaccine?
The infection of a Victorian aged-worker who had received their first COVID vaccine dose isn’t completely surprising. We need two doses for optimal protection.
Answers to key questions about rare blood clots linked to AstraZeneca’s COVID-19 vaccine, including risks, symptoms and whether people who have had one AstraZeneca shot should have a second.
One study found antibody levels were significantly higher in people who received one dose of AstraZeneca then a Pfizer booster dose.
We want to get everybody vaccinated. Opening up to younger age groups could be one way to speed things up — but it will come with logistical challenges too.
The COVID-19 variant responsible for Victoria’s latest outbreak is one of three Indian variant sub-types, which spreads more easily than the original strain. Here’s what we know so far.
The clotting condition has affected one in 88,000 Australians and is less deadly than previously thought.
The increased infectiousness of B16172 could magnify the impact of vaccines being less effective against it.
One of the main fears regarding new SARS-CoV-2 variants is that they might be resistant to immunity granted by vaccines, including RNA vaccines.
Top contributors
-
Professorial Fellow, University of Canberra
-
Senior Research Fellow in Global Health, University of Southampton
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Medicine, University of East Anglia
-
Professor of Health Service Operations, School of Pharmacy & Medical Sciences, University of Bradford
-
Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle
-
Professor, The Children's Hospital at Westmead Clinical School and Sydney Infectious Diseases Institute, University of Sydney
-
Deputy Director of the HUMLOG (Humanitarian Logistics and Supply Chain Management Research) Institute, Hanken School of Economics
-
Distinguished Professor, Professor of Immunology, RMIT University
-
General Practitioner, PhD Candidate, Bond University
-
Professor of Immunology, RMIT University
-
Chair in Epidemiology, Deakin University
-
Principal Lecturer, Microbiology and Biomedical Science Practice, Fellow of the Institute of Biomedical Science, University of Brighton
-
Professor of Intellectual Property Law, Queen Mary University of London
-
Postdoctoral Research Fellow, RMIT University